By Stephen Nakrosis 

Eli Lilly Canada said Tuesday it signed an agreement with the Government of Canada to supply bamlanivimab to treat patients suffering from Covid-19.

The company said it will supply an initial 26,000 doses between December 2020 and February 2021 for US$32.5 million.

"Lilly is taking a data-driven approach to the worldwide allocation of bamlanivimab according to our guiding principles that prioritize countries according to their medical need," the company said, adding "Additional doses will be supplied to Canada on a monthly basis according to the medical need in Canada and the availability of supply."

Lilly said bamlanivimab received authorization to treat certain adult and pediatric patients 12 years of age or older with mild to moderate Covid-19 on November 20.


--Write to Stephen Nakrosis at


(END) Dow Jones Newswires

November 24, 2020 13:25 ET (18:25 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.